CCM
ALLR

Corsair Capital Management’s Allarity Therapeutics ALLR Stock Holding History

Corsair Capital Management’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$18.7K – 155
2025
Q1 		$18.7K Buy
+20,000
New +$20.7K ﹤0.01% 121

Other funds holding ALLR

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Corsair Capital Management's ALLR Position: Q2 2025 in Review

Corsair Capital Management sold out of Allarity Therapeutics (ALLR) in Q2 2025, closing a stake of 20,000 shares — an estimated $18.7K sold.

Corsair Capital Management first reported a position in ALLR in Q1 2025 and held it in 1 quarter. The position peaked at $18.7K in Q1 2025. 10 funds tracked by Wall St. Rank hold ALLR as of Q2 2025.

  • Corsair Capital Management reported no remaining Allarity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corsair Capital Management sold 20,000 Allarity Therapeutics shares in Q2 2025, an estimated $18.7K.
  • Corsair Capital Management first reported a position in Allarity Therapeutics in Q1 2025 and held it in 1 quarter.
  • Corsair Capital Management's Allarity Therapeutics position peaked at $18.7K in Q1 2025.
  • 10 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2025.

Based on Corsair Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.